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Abstract: 5-Fluorouracil (5-FU) remains the gold standard of first-line treatment for colorectal cancer
(CRC). Although it may initially debulk the tumor mass, relapses frequently occur, indicating
the existence of cancer cells that are therapy-resistant and are capable of refueling tumor growth.
To identify mechanisms of drug resistance, CRC stem-like cells were subjected to long-term 5-FU
selection using either intermittent treatment regimen with the IC50 drug dose or continuous treatment
regimen with escalating drug doses. Parental cancer cells were cultivated in parallel. Real-time PCR
arrays and bioinformatic tools were used to investigate gene expression changes. We found the first
method selected for cancer cells with more aggressive features. We therefore transplanted these
cancer cells or parental cells in mice, and again, found that not only did the 5-FU-selected cancer cells
generate more aggressive tumors with respect to their parental counterpart, but they also showed a
different gene expression pattern as compared to what we had observed in vitro, with ID1 the top
upregulated gene. We propose ID1 as a stemness marker pervasively expressed in secondary lesions
emerging after completion of chemotherapy.
Keywords: colorectal cancer; chemoresistance; cancer stem cells
1. Introduction
Current first-line chemotherapy generally consists of cytotoxic agents, like 5-fluorouracil (5-FU),
a uracil analogue that following intracellular conversion into three active metabolites (fluorouridine
triphosphate, fluorodeoxyuridine triphosphate, and fluorodeoxyuridine monophosphate) causes
alterations in RNA processing/function and severe DNA damage [1]. Evidence shows that DNA lesions
are able to trigger apoptosis [2]. However, evasion of both death receptor and mitochondrial pathways
is common in response to stress stimuli [3]. Antiapoptotic mechanisms together with cytoprotective
autophagy [4], upregulated DNA repair pathways [5], and metabolic rewiring [6] allow tumor cells to
thrive in conditions that otherwise would be lethal propagating the disease.
Despite intense studies, one important question still remains open: are resistant cells already
present in the tumor at the time of first treatment or do tumor cells adapt to therapy? Several models
have been proposed to address this important question. The longstanding cancer model, known as
‘clonal evolution’ postulates that tumors arise from a single mutated cell. This cell, in turn, generates an
abnormal offspring that also mutates, forming a mass of genetically diverse tumor cells [7]. From this
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perspective, tumor progression proceeds via a process analogous to Darwinian evolution, where only
cells with advantageous mutations survive and fuel tumor growth [8]. The opposing cancer stem cell
(CSC) theory proposes instead that tumor growth is driven and sustained by a rare population of cells
capable of self-renewal and differentiation [9,10]. While the CSC theory could explain the hierarchical
heterogeneity observed in most tumors, and why some patients suffer relapses after initial successful
therapy [11], clonal evolution driven by genomic instability is likely to play an important role in tumor
progression by allowing CSCs to adapt to environmental, immunologic and pharmacologic cues [12].
Indeed, tumors are dynamic entities and understanding how their cells succeed in offsetting survival
pressures imposed by therapy is of utmost importance for the development of more effective treatments.
Current drug design has been largely focused on initial efficacy, and the effects of drug selective
pressures remain poorly studied. Panels of chemotherapy resistant cancer cell lines have been generated
to investigate the molecular pathways that may be associated with resistance. However, the vast
majority of these studies has been performed on commercially available cell lines and not on primary
cells isolated from patients’ biopsies. Both pulse and incremental drug treatment methods have been
described. However, a comparison of gene expression in the respective treatment-derivatives remains
incomplete. Moreover, to our knowledge, re-transplantation into an in vivo setting of such in vitro
established resistant cell lines has been poorly addressed.
In this manuscript, we used stem cells that were identified, isolated, and characterized in our
laboratory from colorectal cancer (CRC) patients’ specimens [13]. We generated 5-FU resistant cells by
using either intermittent treatment with the IC50 drug dose or continuous treatment with escalating
drug doses. We then used real-time PCR arrays and ingenuity pathway analysis (IPA) to investigate
gene expression changes. Our results indicated that the intermittent treatment with the IC50 of
5-FU could serve as a better model to investigate drug resistance. While biological functions like cell
survival, proliferation, movement, invasion, and migration were predicted by IPA to be inhibited
in cells undergoing continuous treatment with escalating 5-FU doses with respect to parental cells
passaged in parallel, the same functions were predicted to be unaffected in cells undergoing intermittent
treatment with the IC50 5-FU dose. Moreover, while 5-FU resistant cells under continuous treatment
with escalating drug doses were predicted to be more prone to cell death with respect to parental
cells, cell cycle progression was not predicted to be delayed in the other cell group despite DNA
damage, suggesting a propensity to genomic instability, as previously described [13]. Tumor xenografts
were generated from both parental and resistant cells undergoing intermittent treatment with the
IC50 5-FU dose with the resistant cells generating more aggressive phenotypes. The gene expression
changes observed in the in vivo xenograft setting were compared to those observed in the in vitro
setting. We found in vivo and in vitro gene expression patterns to differ, indicating a capability for
5-FU resistant cells to dynamically adapt and evolve. We identified ID1 as the top upregulated gene in
the tumor generated by 5-FU resistant cells.
2. Results
2.1. Establishment of 5-FU Resistant Human CRC Stem-Like Cells
CRC stem cells were derived from five human metastatic cancers (Tu11, Tu14, Tu27, Tu28, and
Tu42) using a feeder-dependent cell culture system, previously described by our laboratory [13].
In order to establish chemotherapeutic resistant cells, we first tested the ability of tumor cells to grow
in the absence of the feeder layer. Complete depletion of the feeder cells was obtained at the second
passage of tumor cells on plastic (data not shown). At this passage, tumor cells often showed a high
ratio of nucleus to cytoplasm, prominent nucleoli, and colony morphology similar to that of embryonic
stem cells (data not shown). However, following repeated passages, colonies with these characteristics
became less frequent. These passaged feeder-free cells will be hereinafter referred to as ‘stem-like
cells’. After one passage on the feeder layer, and two passages on plastic, all five cell lines were treated
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with serial dilutions of 5-FU to establish an IC50 dose. Low 5-FU doses (10-25 µM) surprisingly led to
increased cell numbers in most of the cultures (Figure 1A).
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Figure 1. Establishment of 5-FU resistant human colorectal cancer (CRC) stem-like cells. (A) Line 
graphs showing cell viability (%) of Tu11, Tu14, Tu27, Tu28, and Tu42 CRC stem-like cells (P stands 
for passage) treated with vehicle or serial dilutions (10–250 µM) of 5-FU. Data are expressed as mean 
percentage (± SD) of cell numbers relative to control culture. (B–D) Line graphs showing cell 
viability (%) of consecutive passages of Tu27, Tu28, and Tu42 CRC stem-like cells treated with 
vehicle or serial dilutions (10–500 µM) of 5-FU. Data are expressed as mean percentage (± SD) of cell 
numbers relative to control culture. (E) Line graph showing the expression intensity of 
PTEN/MMAC1/TEP1 in short-term feeder-expanded Tu11, Tu14, Tu27, Tu28, and Tu42 CRC stem 
cells obtained using three different microarray probes (204054_at; 217492_s_at; 204053_x_at). 
We found the subpopulation of cells expressing the cancer-initiating cell marker EpCAM [14] 
to proliferate in response to low 5-FU doses. Indeed, a higher number of cells stained positive for 
EpCAM after treatment, and only EpCAM positive cells also stained positive for the proliferation 
cell marker Ki-67 (data not shown). Unfortunately, we were not able to further propagate Tu11 and 
Tu14 cells. In addition, Tu28 cells survived for only two more passages on plastic, while Tu27 and 
Tu42 cells were easily expanded (Figure 1 B–D). Along with passages, these cells became less 
resistant to 5-FU (IC50 for Tu27 = 250 µM; IC50 for Tu42 = 100 µM) (Figure 1B,D). 
Once the IC50 dose for 5-FU was established, we attempted the generation of 5-FU resistant 
cells by either intermittent treatment with the IC50 drug dose (hereinafter called R1 cells; two 
pulses of 100 µM 5-FU were given) or continuous treatment with escalating drug doses (hereinafter 
called R2 cells; six doses were given, starting with the 1/20 IC50 dose up to the IC50 dose). 
Unfortunately, we were not able to establish stable 5-FU resistant Tu27 cells: as early as 5 weeks 
after the start of treatment, all cells died. Conversely, we successfully generated resistant Tu42 cells. 
We retrospectively reviewed microarray data from short-term feeder-expanded Tu11, Tu14, 
Tu27, Tu28, and Tu42 CRC stem cells to investigate why we failed to generate resistant cancer cell 
lines most of the time. We found that with respect to the other cell lines, Tu42 cells downregulated 
the tumor suppressor PTEN/MMAC1/TEP1 (PTEN, phosphatase deleted on chromosome ten; 
MMAC1, mutated in multiple advanced cancers; TEP1, tensin-like phosphatase) (Figure 1E). Thus, 
PTEN/MMAC1/TEP1 status might be a crucial determinant of 5-FU resistance in CRC. 
Low 5-FU doses (up to the 20 µM) resulted in accumulation of large foci in Tu42 cells (Figure 
2A, middle panels). 
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We found the subpopulation of cells expressing the cancer-initiating cell marker EpCAM [14]
to proliferate in response to low 5-FU doses. Indeed, a higher number of cells stained positive for
EpCAM after treatment, and only EpCAM positive cells also stained positive for the proliferation cell
marker Ki-67 (data not shown). Unfortunately, we were not able to further propagate Tu11 and Tu14
cells. In addition, Tu28 cells survived for only two more passages on plastic, while Tu27 and Tu42 cells
were easily expanded (Figure 1B–D). Along with passages, these cells became less resistant to 5-FU
(IC50 for Tu27 = 250 µM; IC50 for Tu42 = 100 µM) (Figure 1B,D).
Once the IC50 dose for 5-FU was established, we attempted the generation of 5-FU resistant
cells by either intermittent treatment with the IC50 drug dose (hereinafter called R1 cells; two pulses
of 100 µM 5-FU were given) or continuous treatment with escalating drug doses (hereinafter called
R2 cells; six doses were given, starting with the 1/20 IC50 dose up to the IC50 dose). Unfortunately,
we were not able to establish stable 5-FU resistant Tu27 cells: as early as 5 weeks after the start of
treatment, all cells died. Conversely, we successfully generated resistant Tu42 cells.
We retrospectively reviewed microarray data from short-term feeder-expanded Tu11, Tu14, Tu27,
Tu28, and Tu42 CRC stem cells to investigate why we failed to generate resistant cancer cell lines most
of the time. We found that with respect to the other cell lines, Tu42 cells downregulated the tumor
suppressor PTEN/MMAC1/TEP1 (PTEN, phosphatase deleted on chromosome ten; MMAC1, mutated
in multiple advanced cancers; TEP1, tensin-like phosphatase) (Figure 1E). Thus, PTEN/MMAC1/TEP1
status might be a crucial determinant of 5-FU resistance in CRC.
Int. J. Mol. Sci. 2019, 20, 1817 4 of 23
Low 5-FU doses (up to the 20 µM) resulted in accumulation of large foci in Tu42 cells (Figure 2A,
middle panels).
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Figure 2. Features of the human colorectal cancer (CRC) stem-like cell line Tu42 under low 5-FU 
doses. (A) Merged images of phase contrast (PhC) and Hoechst-stained nuclei (DNA) of parental 
(top) or 20 µM 5-FU resistant (center) Tu42 cells. Boxed areas are shown on the right at higher power 
and indicate the presence of distinct large foci in response to low-dose 5-FU. Immunofluorescence 
staining for Wheat germ agglutinin (WGA), Laminin B1 (LMNB1), SF2, Fibrillarin (FBR), 
Nucleostemin (NS), Nucleophosmin (NPM), or PML in 20 µM 5-FU resistant Tu42 cells (bottom) 
suggested high nucleus-to-cytoplasm ratio, the presence of nuclear buds, and identified the 
previously observed foci as nucleolar structures. Nuclei were counterstained using Hoechst. 
Pictures are representative of three independent experiments. (B) Immunofluorescence staining for 
Ki-67 or TRA-2-49 of parental (top) or 20 µM 5-FU resistant (bottom) Tu42 cells indicated the 
accumulation of Ki-67 in nucleolar regions of resistant cells and the upregulation of TRA-2-49 in the 
same cells with respect to parental cells. Nuclei were counterstained using Hoechst. Pictures are 
representative of three independent experiments. (C) Merged images of phase contrast (PhC), 
EpCAM, and Mucin2 (Muc2), or PhC, EpCAM, and Villin of parental (top) or 20 µM 5-FU resistant 
(bottom) Tu42 cells indicated that resistant cells downregulate EpCAM, Muc2, and Villin, as 
compared to parental cells. Pictures are representative of three independent experiments. (D) Bright 
field (BF) images of live unstained parental (top left) or 20 µM 5-FU resistant (top right) Tu42 cells 
forming organoids in Matrigel, and immunofluorescence staining for EpCAM/Muc2 (center) or 
EpCAM/Villin (bottom) in their respective frozen sections indicated resistant cells reacquire EpCAM 
expression in three-dimensional (3D) cell culture but fail to generate organoids with a central lumen. 
Pictures are representative of three independent experiments. 
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cytoplasm ratio in these cells, as well as the presence of nuclear buds, and identified the previously 
observed foci as nucleolar structures (Figure 2A, bottom panels). Interestingly, the nucleolar 
structures were highly reactive for Ki-67 (Figure 2B), indicating that the cells were likely in 
interphase and responding to DNA damage [15,16]. Moreover, with respect to parental cells, 20 µM 
5FU-resistant cells upregulated the pluripotent stem cell marker TRA-2-49 [17] (Figure 2B) and 
downregulated EpCAM, Mucin 2 (Muc2, the major secretory mucin synthesized and secreted by 
goblet cells [18]), and Villin (a cytoskeletal protein and a differentiation marker [19]) (Figure 2C). 
Interestingly, resistant cells could reacquire EpCAM expression when directed to form organoids in 
Matrigel, although they failed to generate organoids with a central lumen (Figure 2D). These 
observations suggest two possible outcomes: a) low 5-FU doses given under two-dimensional 
culture conditions reprogram CRC stem-like cells into less differentiated CSCs and this 
reprogramming is partially reversible when the cells are cultured in three-dimensional (3D) 
matrices; or b) the selective pressure under low 5-FU doses allows survival of less differentiated 
CSCs already present in the culture. 
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Immunofluorescence staining for Wheat germ agglutinin (WGA), Laminin B1 (LMNB1),
SF2, Fibrillarin (FBR), Nucleostemin (NS), Nucleophosmin (NPM), or PML suggested high
nucleus-to-cytoplasm ratio in these cells, as well as the presence of nuclear buds, and identified
the previously observed foci as nucleolar structures (Figure 2A, bottom panels). Interestingly, the
nucleolar structures were highly reactive for Ki-67 (Figure 2B), indicating that the cells were likely
in interphase and responding to DNA damage [15,16]. Moreover, with respect to parental cells,
20 µM 5FU-resistant cells upregulated the pluripotent stem cell marker TRA-2-49 [17] (Figure 2B)
and downregulated EpCAM, Mucin 2 (Muc2, the major secretory mucin synthesized and secreted
by goblet cells [18]), and Villin (a cytoskeletal protein and a differentiation marker [19]) (Figure 2C).
Interestingly, resistant cells could reacquire EpCAM expression when directed to form organoids
in Matrigel, although they failed to generate organoids with a central lumen (Figure 2D). These
observations suggest two possible outcomes: a) low 5-FU doses given under two-dimensional culture
conditions reprogram CRC stem-like cells into less differentiated CSCs and this reprogramming is
partially reversible when the cells are cultured in three-dimensional (3D) matrices; or b) the selective
pressure under low 5-FU doses allows survival of less differentiated CSCs already present in the culture.
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2.2. Differential Morphology, Gene Expression Profiles, and Biological Functions in 5-FU Resistant Tu42 CRC
Stem-Like Cells as Compared to Parental Cells
While parental cells passaged in parallel progressively acquired a differentiated morphology
comprising crypt–villus structures (Figure 3A, top image), R1 cells organized in round colonies with
defined edges following 8 months of 5-FU-induced selection pressure (Figure 3A, middle image).
Conversely, R2 cells treated with increasing drug doses (up to the 20 µM 5-FU dose) were initially
organized in round colonies (data not shown) and eventually showed a more differentiated morphology
that was similar to the parental cells (Figure 3A, bottom image).
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Figure 3. Differential morphology, gene expression profiles and biological functions in 5-FU resistant
Tu42 colorectal cancer (CRC) stem-like cells as compared to parental cells. (A) Phase contrast images of
parental (P) or 5-FU resistant Tu42 cells selected over an 8-month period by either intermittent treatment
with the IC50 drug dose (R1; two pulses of 100 µM 5-FU were given) or continuous treatment with
escalating drug doses (R2; six doses were given, starting with the 1/20 IC50 dose up to the IC50 dose).
(B) List of the top up- or downregulated genes in 5-FU resistant Tu42 cells as compared to parental cells
obtained by real-time PCR arrays. (C) Biological functions arranged in alphabetical order predicted by
IPA to be activated (red) or inhibited (green) in 5-FU resistant Tu42 cells as compared to parental cells.
(D) Bar graphs show fold regulation (positive/negative fold changes calculated from two technical
replicates) of genes involved in DNA damage and cell cycle, apoptosis, stemness, invasion, metastasis
and angiogenesis, mTOR pathway, other pathways, metabolism, and chromatin remodeling in 5-FU
resistant Tu42 cells as compared to parental cells (grey bars: R1 cells versus parental cells; black bars:
R2 cells versus parental cells). (E) Representative amplification plots of EIF4B, EGF, and MYCN in
parental and 5-FU resistant Tu42 cells. ∆Rn is plotted against PCR cycle number. (F) Flow cytometry
histograms showing expression of CD24 and CD227 (Muc1) in parental (black histograms) and R1
(red histograms) cells (grey histograms indicate unstained control). Histograms are representative
of three independent experiments. (G) Scatter dot plot with mean and SEM showing percentages of
phospho-S6RP (pS6RP-S235/236 and pS6RP-S240/244) positive cells/colony generated by parental, R1,
or R2 cells. Each dot represents a colony. Statistical significance, calculated using unpaired t-test with
Welch’s correction, is shown (ns, p > 0.05; **, p ≤ 0.01; ***, p ≤ 0.001). Representative pS6RP-S235/236
and pS6RP-S240/244 stained colonies are shown at the right of each graph. Data are representative of
three independent experiments.
We isolated RNA from all three-cell groups (parental, R1, and R2) derived from Tu42, and
analyzed 588 genes using several RT2 Profiler PCR arrays in 96-well format. Each 96-well plate included
84 pathway- or disease-focused genes, as well as five housekeeping genes. Moreover, each plate
included control elements for genomic DNA contamination detection, RNA sample quality, and three
replicate controls to check general PCR performance. We found the system to be very reliable and
reproducible, with Pearson correlation of gene expression between two technical replicates >0.99
(Supplementary Figure S1). Figure 3B shows the list of top up/downregulated genes in R1 and R2 cells
with respect to parental cells. Both resistant cell groups upregulated CA9, MUC1, and CD24, while they
downregulated HEY1, NANOG, and IL8. Biological functions including cell cycle progression, DNA
replication, G1/S phase transition, metabolism of DNA, mitosis, and S phase were predicted by IPA
to be activated in R1 cells with respect to parental cells (Figure 3C). Conversely, biological functions
including cell movement, cell proliferation, cell survival, cell viability, invasion of cells, metastatic solid
tumor, migration of cells, repair of DNA, and self-renewal of cells were predicted to be inhibited in
R2 cells with respect to parental cells (Figure 3C). R2 cells were also predicted to activate biological
functions like apoptosis and cell death (Figure 3C). Thus, the intermittent treatment with the IC50 drug
dose selected for cells with more aggressive features than the continuous treatment with escalating
drug doses. Genes expressed differentially between parental and R1 cells or parental and R2 cells are
shown in Figure 3D. Official full names for each reported gene are listed in Table 1.
Table 1. Official full names for genes differentially expressed in vitro.
Official Symbol Official Full Name
ABCC1 ATP binding cassette subfamily C member 1
ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase
ACSL4 Acyl-CoA synthetase long chain family member 4
AKT2 AKT serine/threonine kinase 2
ATM ATM serine/threonine kinase
ATR ATR serine/threonine kinase
ATRX ATRX, chromatin remodeler
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Table 1. Cont.
Official Symbol Official Full Name
AURKA Aurora kinase A
AURKB Aurora kinase B
BBC3 BCL2 binding component 3
BCL2L1 BCL2 like 1, Bcl-xl
BIRC5 Baculoviral IAP repeat containing 5, Survivin
BLM BLM RecQ like helicase
BMP4 Bone morphogenetic protein 4
CA9 Carbonic anhydrase 9
CBX1 Chromobox 1
CCL5 C-C motif chemokine ligand 5
CD24 CD24 molecule
CDC25A Cell division cycle 25A
CDC42 Cell division cycle 42
CDK1 Cyclin dependent kinase 1
CDK2 Cyclin dependent kinase 2
CDK4 Cyclin dependent kinase 4
CDK5 Cyclin dependent kinase 5
CEBPD CCAAT enhancer binding protein delta
CHD3 Chromodomain helicase DNA binding protein 3
CHEK1 Checkpoint kinase 1
CHEK2 Checkpoint kinase 2




DDIT3 DNA-damage inducible transcript 3
DNMT1 DNA methyltransferase 1
DNMT3A DNA methyltransferase 3 alpha
DNMT3B DNA methyltransferase 3 beta
DOT1L DOT1 like histone lysine methyltransferase
EGF Epidermal growth factor
EIF4B Eukaryotic translation initiation factor 4B
EIF4E Eukaryotic translation initiation factor 4E
ERBB2 Erb-b2 receptor tyrosine kinase 2
ESCO2 Establishment of sister chromatid cohesion N-acetyltransferase 2
FABP1 Fatty acid binding protein 1
FANCA FA complementation group A
FANCG FA complementation group G
FAS Fas (TNF receptor superfamily member 6)
FEN1 Flap structure-specific endonuclease 1
FGFR2 Fibroblast growth factor receptor 2
FOSL1 FOS like 1, AP-1 transcription factor subunit
FOXP1 Forkhead box P1
FZD7 Frizzled class receptor 7
GADD45A Growth arrest and DNA damage inducible alpha
GCLC Glutamate-cysteine ligase catalytic subunit
GCLM Glutamate-cysteine ligase, modifier subunit
GSR Glutathione-disulfide reductase
HAT1 Histone acetyltransferase 1
HDAC1 Histone deacetylase 1
HDAC11 Histone deacetylase 11
HDAC4 Histone deacetylase 4
HDAC6 Histone deacetylase 6
HDAC7 Histone deacetylase 7
HDAC9 Histone deacetylase 9
HES1 Hes family bHLH transcription factor 1
HEY1 Hairy/enhancer-of-split related with YRPW motif 1
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Table 1. Cont.
Official Symbol Official Full Name
HMOX1 Heme oxygenase 1
ID1 Inhibitor of DNA binding 1, HLH protein
IL8 Interleukin 8
IRS1 Insulin receptor substrate 1
ITGB1 Integrin Subunit Beta 1
JAG1 Jagged 1
KAT2A Lysine acetyltransferase 2A
KAT2B Lysine acetyltransferase 2B
KAT6B Lysine acetyltransferase 6B
KDM5C Lysine demethylase 5C
KITLG KIT ligand
LDHA Lactate dehydrogenase A
LFNG LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase
LIG1 DNA ligase 1
MAML1 Mastermind like transcriptional coactivator 1
MCL1 MCL1, BCL2 family apoptosis regulator
MERTK MER proto-oncogene, tyrosine kinase
MLH1 MutL homolog 1
MMP7 Matrix metallopeptidase 7
MUC1 Mucin 1
MYCN MYCN proto-oncogene, bHLH transcription factor
NANOG Nanog
NCOA1 Nuclear receptor coactivator 1
NOTCH2 Notch 2
NQO1 NAD(P)H quinone dehydrogenase 1
PARP1 Poly(ADP-ribose) polymerase 1
PCNA Proliferating cell nuclear antigen
PLAUR Plasminogen activator, urokinase receptor
PLD2 Phospholipase D2
PLK1 Polo like kinase 1
PPP2R4 Phosphotyrosyl phosphatase activator
PRAS40 Proline-rich Akt substrate 40 kDa
PRKCE Protein kinase C epsilon
PRMT5 Protein arginine methyltransferase 5
PROM1 Prominin 1, CD133
RAPTOR Regulatory associated protein of mTOR
RHOB Ras homolog family member B
RPA1 Replication protein A1
RPS6KA2 Ribosomal protein S6 kinase A2
RPS6KB2 Ribosomal protein S6 kinase B2
SETD1A SET domain containing 1A
SETD1B SET domain containing 1B
SMC1A Structural maintenance of chromosomes 1A
STAT3 Signal transducer and activator of transcription 3
SUV39H1 Suppressor of variegation 3-9 homolog 1
TGFBR1 Transforming growth factor beta receptor 1
TNFSF10 TNF superfamily member 10, TRAIL
VEGFA Vascular endothelial growth factor A
VEGFD Vascular endothelial growth factor D
XRCC2 X-ray repair cross complementing 2
2.2.1. DNA Damage and Cell Cycle
Whereas normal cells or drug-responsive cancer cells repair DNA damage and go into senescence
or apoptosis, loss of cell cycle checkpoints allows cancer cells to proliferate and perpetuate harmful
mutations [10]. We analyzed multiple DNA damage and cell cycle-related genes in resistant cell
derivatives. The top upregulated genes of these categories in R1 cells included CDK1, CDC25A, BLM,
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and AURKB. CDK1 and CDC25A force proliferation despite drug-induced DNA damage, due to their
ability to completely disable cell-cycle checkpoints [20,21], and are therefore associated with tumor
progression and drug resistance [22]. The BLM product is a helicase of the RECQ family with roles
in DNA replication and repair [23]. AURKB overexpression is associated with multinucleation and
polyploidy and therefore has a high correlation with genomic instability [24]. CDK1 and BLM were
also upregulated in R2 cells, although to a lower extent. Finally, both R1 and R2 cells downregulated
DDIT3, which has been implicated in stress responses leading to apoptosis [25].
2.2.2. Apoptosis
DNA-damaging agents induce apoptosis through both the mitochondrial and the death receptor
pathway. Surprisingly, both R1 and R2 cells upregulated FAS and TNFSF10. While the overwhelming
majority of studies on FAS and TNFSF10 have explored their role as initiators of apoptosis, sporadic
reports suggest that they could actually be drivers of cell proliferation, migration, and invasion, and
therefore contributors of tumor progression [26]. The tumorigenic activity of FAS is likely mediated
by a pathway involving JNK and c-Jun. [27]. On the other hand, TNFSF10 can antagonize apoptosis
induction and enhance proliferation through activation of the NF-κB pathway [28]. R1 cells also
upregulated BIRC5. Mostly known as an anti-apoptotic factor, BIRC5 additionally controls cell division
by regulating the G2/M phase [29]. The expression levels of the anti-apoptotic genes BBC3 and MCL1
were reduced in both resistant cell groups, especially in R2 cells. Moreover, R2 cells also downregulated
an additional anti-apoptotic gene, BCL2L1.
2.2.3. Stemness
Both R1 and R2 cells upregulated the putative CSC marker CD24 and PROM1, to a lower
extent. Both markers correlate with invasiveness in CRC [30]. KITLG, encoding the ligand for the
c-kit proto-oncogene [31], was highly upregulated in R1 cells, but not in R2 cells. Both cell groups
downregulated the pluripotent stem cell marker NANOG [32], especially R2 cells. Finally, ABCC1,
which encodes a multidrug resistance-associated protein [33], was downregulated in R2 cells but not
in R1 cells.
2.2.4. Invasion, Metastasis, and Angiogenesis
R1 cells showed strong upregulation of three genes positively associated with migration, invasion
and metastasis: CCL5 [34], MUC1 [35], and MMP7 [36]. While MUC1 was also upregulated in R2
cells (although to a much lower extent than in R1 cells), CCL5 was unchanged and MMP7 was
highly downregulated in R2 cells. Another gene, associated with cell invasiveness, CHD3 [37], was
downregulated in R2 cells while unchanged in R1 cells. Genes encoding proteins with oncogenic
characteristics including MERTK [38], ID1 [39], FZD7 [40], NCOA1 [41], PLAUR [42], and TGFBR1 [43]
were downregulated in R2 cells while unchanged or slightly changed in R1 cells. Another gene
encoding an oncogene, ERBB2 [44], was upregulated in R1 cells while unchanged in R2 cells. Genes
with a tumor suppressive role including FOXP1 [45] and FGFR2 [46] were downregulated in both cell
groups. Pro-angiogenetic genes, including VEGFD [47], FOSL [48], and IL8 [49] were decreased in both
cell groups, especially in R2 cells. Another pro-angiogenetic gene, VEGFA [47], was also reduced in
both cell groups, but its levels were lower in R1 cells.
2.2.5. mTOR Pathway and Other Pathways
Several genes implicated in the mTOR pathway [50,51] were downregulated in R2 cells and
unchanged or slightly changed in R1 cells. With the exception of HEY1, several genes encoding members
of the Notch family (JAG1, LFNG, MAML1, NOTCH2 [52]) showed a more enhanced downregulation
in R2 cells than R1 cells. Notch pathway activation has been suggested to function as a protective
mechanism in response to chemotherapy [53]. Finally, STAT3 was slightly upregulated in R1 cells.
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2.2.6. Metabolism
Metabolic alterations are common in tumors. These include increased uptake of glucose, amino
acids, and lipids. Under normal physiological conditions, glucose is catabolized to pyruvate. Most
of the pyruvate undergoes several changes to become acetyl-CoA and enter the Kreb’s cycle. Only
a small amount of pyruvate is converted to alanine or lactate. In contrast, tumor cells prefer lactic
acid fermentation as a source of energy; that is, they convert pyruvate to lactate even under normoxic
conditions. This phenomenon, referred to as the Warburg effect [54], is possible thanks to the
upregulation of LDHA, a key glycolytic enzyme [55]. We found LDHA to be upregulated in both
cell groups, especially in R2 cells. Carbon dioxide is released during aerobic glycolysis, leading to
a decrease in the intracellular and extracellular pH. Studies have shown that cancer cells adapt to
this acidic milieu thanks to the activity of carbonic anhydrases including CA9, which catalyzes the
conversion of carbon dioxide into bicarbonate [56]. CA9 was highly upregulated in both groups,
especially in R2 cells. Lipid metabolism is often elevated in cancer cells and plays an important role
in their growth and malignancy. FABP1, which encodes a protein critical for fatty acid uptake and
intracellular transport [57] was upregulated in both cell groups, especially in R2 cells. Other genes
whose products are lysosomal proteases involved in lipid metabolism (CTSB, CTSD, and CTSL [58])
were also downregulated in R2 cells. Finally, resistant cells also showed alterations of genes encoding
proteins involved in fatty acid synthesis (ACSL4 [59]) or oxidation (CPT2 [60]), as well as glutathione
metabolism (GCLC, GCLM, GSR, and NQO1 [61]) and oxidative stress (HMOX1 [62]).
2.2.7. Chromatin Remodeling
The chromatin remodeling genes which showed the greatest changes in R1 cells were ESCO2,
CBX1, and SUV39H1, which were all upregulated. ESCO2 is critical for the cohesion of sister chromatids
during DNA replication and DNA damage repair [63]. Besides its role in DNA repair, CBX1 has
opposite effects in differentiated cells and pluripotent stem cells: it is required for the differentiation
of differentiated cells while it maintains pluripotency in pluripotent stem cells [64]. Conversely,
SUV39H1 regulates cell migration and tumor growth [65]. While ESCO2 was also upregulated in R2
cells (although 2.5-fold less than in R1 cells), R2 cells highly downregulated the chromatin remodeling
genes HDAC4 and DOT1L. HDAC4 promotes growth of colon cancer cells via repression of p21 [66].
DOT1L deficiency leads to the dysregulation of cell cycle regulators and G1 cell cycle arrest [67].
Collectively, our findings suggested that R1 cells might have had a more resistant phenotype than
R2 cells. This hypothesis was further supported by the finding that R2 cells lost the expression of
EIF4B (Figure 3E), a substrate of the mTOR pathway, required for cell proliferation and survival of
cancer cells [68]. Our analysis also identified EGF and MYCN as two de novo expressed genes in the
population of resistant cells (Figure 3E). EGF has been reported to induce MYCN expression and to
favor tumor growth [69].
Overexpression of CD24 and Muc1 (CD227) in R1 cells was confirmed using flow cytometry
(Figure 3F). Moreover, we confirmed unaltered and decreased mTOR activity in R1 and R2 cells,
respectively, by staining for the downstream mTOR target S6RP. We found that most of the
phospho-S6RP (pS6RP-S235/236 and pS6RP-S240/244) expression localized at the cell colonies’ edges
(Figure 3G). Mathematical models suggest that the growth in size of a cellular colony is due to
a ring of growing and proliferating cells at the colony edge [70]. The mTOR signaling plays a
major role in promoting cell-cycle progression, and downregulation of phospho-S6RP is a feature
of slow-cycling cancer cells [71]. Thus, we hypothesize that parental and R1 cell-derived colonies
contained proliferating cells at their edges expressing pS6RP. Proliferation is reduced in R2 cells, and
this might be an effect of chemotherapy-induced mTOR pathway downregulation. Importantly, 5-FU
chemoresistance in R1 cells was maintained over time, as indicated by high 5-FU IC50 value two
months after their establishment (Supplementary Figure S2).
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2.3. Differential Histology, Gene Expression Profiles, and Biological Functions of 5-FU Resistant Tu42 CRC
Stem-Like Cells as Compared to Parental Cells In Vitro and In Vivo
We next established tumor xenografts using both parental and R1 cells. Morphologically,
the tumors were different (Figure 4A).
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Figure 4. Differential histology, gene expression profiles and biological functions in R1 cells versus
parental cells in vitro and in vivo. (A) PFA-fixed, paraffin-embedded serial sections of parental or
R1 cell-derived tumor xenografts stained with hematoxylin and eosin (H&E) or alcian blue (AB).
Characteristics of R1 cell-derived tumor xenograft include: a pseudostratified glandular epithelium
with marked nuclear atypia and cellular ov rlapping and few ucinous goblet cells. Parental
cell-derived tumor xenograft shows lesser degree f architectural abno maliti i cluding glands with
low-grade cytologic dysplasia and abundant goblet cells. Pictures are representative of five histological
sections/tumor. (B) Graph shows fold regulation (positive fold changes) of de novo expressed genes in
R1 cell- versus parental cell-derived tumor xenograft. (C) List of the top up- or downregulated genes in
R1 cell- versus parental cell-derived tumor xenograft obtained by real-time PCR arrays. (D) Biological
functions ranked by p-value (from smallest or strongest to largest or weakest) redicted by IPA to be
activated (red) or inhibited (gr en) in R1 cell- versus parental ell-derived tumor xenogr ft. (E) Venn
diagra s show the lists of diverging and overlapping genes (for each of the following categories:
DNA damage and cell cycle; apoptosis; stemness; invasion, metastasis and angiogenesis; mTOR
pathway; other pathways; metabolism and chromatin remodeling) whose expression was altered (≥2.0
or ≤−2.0) in R1 cells as compared to parental cells in vitro and in vivo. Upregulated genes are in
red, downregulated genes are in green. Graphs on the right of each Venn diagram show differential
regulation of selected genes in vitro (grey bars) and in vivo (black bars).
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Characteristics of R1 cell-derived tumor xenograft included a pseudostratified glandular
epithelium with marked nuclear atypia and cellular overlapping, and few mucinous goblet cells.
Conversely, parental cell-derived tumor xenograft showed a lesser degree of architectural abnormalities
including glands with low-grade cytologic dysplasia and abundant goblet cells (Figure 4A). We therefore
ran the same PCR arrays as before in the two tumor xenografts and compared their expression profiles.
Table 2 lists the official full names for each gene found to be differentially regulated.
Table 2. Official full names for genes differentially expressed in vivo.
Official Symbol Official Full Name
ABCC1 ATP binding cassette subfamily C member 1
BCL2L1 BCL2 like 1, Bcl-xl
BMP2 Bone morphogenetic protein 2
BMP4 Bone morphogenetic protein 4
CA9 Carbonic anhydrase 9
CEBPD CCAAT enhancer binding protein delta
CDC25A Cell division cycle 25A
CHD3 Chromodomain helicase DNA binding protein 3
DNMT3A DNA methyltransferase 3 alpha
DOT1L DOT1 like histone lysine methyltransferase
ERBB2 Erb-b2 receptor tyrosine kinase 2
EIF4B Eukaryotic translation initiation factor 4B
FAS Fas (TNF receptor superfamily member 6)
FABP1 Fatty acid binding protein 1
FGFR2 Fibroblast growth factor receptor 2
FOXP1 Forkhead box P1
FZD7 Frizzled class receptor 7
HDAC11 Histone deacetylase 11
HDAC9 Histone deacetylase 9
ID1 Inhibitor of DNA binding 1, HLH protein
IGF1 Insulin like growth factor 1
IGF1R Insulin like growth factor 1 receptor
IGFBP3 insulin like growth factor binding protein 3
IRS1 Insulin receptor substrate 1
JAG1 Jagged 1
KIT KIT proto-oncogene receptor tyrosine kinase
LFNG LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase
NANOG Nanog
NOTCH1 Notch 1
NFKB1 Nuclear factor kappa B subunit 1
PTEN Phosphatase and tensin homolog
PLD2 Phospholipase D2
PARP1 Poly(ADP-ribose) polymerase 1
PRAS40 Proline-rich Akt substrate 40 kDa
PROM1 Prominin 1, CD133
PTGS2 Prostaglandin-endoperoxide synthase 2
PRKCB Protein kinase C beta
PRKCE Protein kinase C epsilon
RHOB Ras homolog family member B
RRAGA Ras related GTP binding A
RAPTOR Regulatory associated protein of mTOR
RPS6KA2 Ribosomal protein S6 kinase A2
RPS6KB2 Ribosomal protein S6 kinase B2
SERPINE1 Serpin family E member 1
SETD1B SET domain containing 1B
SLC2A1 Solute carrier family 2 member 1, GLUT-1
TWIST1 Twist family bHLH transcription factor 1
TWIST2 Twist family bHLH transcription factor 2
YAP1 Yes associated protein 1
ZEB2 Zinc finger E-box binding homeobox 2
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While we could not detect any mRNA transcript for IGF1, IGFBP3, KIT, PRKCB, PTEN, PTGS2,
SERPINE, TWIST1, TWIST2, and ZEB2 in vitro, all these genes were expressed in vivo (Figure 4B),
possibly indicating different promoters’ methylation status or different microRNA regulation in the
two conditions. Importantly, all the above-mentioned genes were upregulated in R1 cell-derived tumor
xenograft with respect to parental cell-derived tumor xenograft (Figure 4B) and some of them (KIT,
SERPINE, TWIST1, TWIST2, and ZEB2) could even be included in the top upregulated gene list of R1
cell-derived tumor xenograft versus parental cell-derived tumor xenograft (Figure 4C). These genes
encode for proteins with well-known roles in cancer progression and normal stem cell maintenance
(KIT [72]), angiogenesis (SERPINE [73]), and epithelial-mesenchymal transition (TWIST1, TWIST2, and
ZEB2 [74,75]). The list of top upregulated genes in R1 cell-derived tumor xenograft versus parental
cell-derived tumor xenograft also included ID1 and BMP4 (Figure 4C). Moreover, FAS and CDKN1A
were identified as the top downregulated genes in R1 cell-derived tumor xenograft versus parental
cell-derived tumor xenograft (Figure 4C). Biological functions associated with cancer were predicted
by IPA to be activated in R1 cell-derived tumor xenograft versus parental cell-derived tumor xenograft,
while biological functions associated with death were predicted to be inactivated (Figure 4D).
Interestingly, we found that only a few of the genes which were upregulated in vitro by R1 cells
were also upregulated in vivo. These included CDC25A, PARP1, PROM1, ERBB2, CA9, and HDAC9
(Figure 4E). None of the genes which were downregulated in vitro were also downregulated in vivo.
Opposing trends were observed for FAS, NANOG, CCL5, CEBPD, FGFR2, FOXP1, JAG1, and FABP1.
As expected, in vivo, fewer of the genes associated with DNA damage and cell cycle, metabolism,
or chromatin remodeling were changed. The greatest changes affected the invasion, metastasis and
angiogenesis gene category, with ID1 and BMP4 being the most two upregulated genes. Furthermore,
many genes in the mTOR pathway category were upregulated in vivo by R1 cells. Most of these genes
(EIF4B, PRAS40, RAPTOR, RPS6KA2, RPS6KB2, and RRAGA) are directly or indirectly involved in the
mTORC1 pathway [50]. This agrees with our previous observation that mTORC1 pathway activation
is a feature of colorectal tumors [76].
2.4. ID1-Expressing Cell Enrichment Is a Feature of 5-FU Resistant Tu42 Cell-Derived Tumor Xenograft
This study has identified ID1 as the top upregulated gene in R1 cell-derived tumor xenograft.
Using immunohistochemistry, we confirmed ID1 overexpression at the protein level (Figure 5A).
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Figure 5. ID1-expressing cell enrichment is a feature of 5-FU resistant Tu42 cell-derived tumor xenograft.
(A) PFA-fixed, paraffin-embedded serial sections of parental or R1 cell-derived tumor xenografts stained
with ID1, ID2, ID3, ID4, or BMP4 antibodies (DAB, brown color). Pictures are representative of five
histological stains per tumor. (B) Dot plot with line in the mean showing ID1 expression obtained
from quantile normalized microarray datasets of short-term feeder-expanded normal small or large
intestinal stem cells (SiSCs and LiSCs, respectively) and CRC stem cells (CoCSCs). Each dot represents
one sample. (ns. p > 0.05; ** p ≤ 0.01).
Interestingly, both ID1 positive and negative cells could be observed, leading to the speculation
that ID1 could mark a subpopulation of cells with stemness features in the tumor. To establish ID1
as a stemness marker, the presence of ID1 in normal intestinal stem cells and its overexpression in
cancerous intestinal stem cells need first to be demonstrated. To this purpose, we retrospectively
compared the levels of ID1 in short-term feeder-expanded primary epithelial cells isolated from human
fetal small or large intestine to short-term feeder-expanded primary epithelial cells isolated from CRC
biopsies. All three-cell types were cultured under conditions promoting the enrichment of cells with
stemness features and are herein indicated as SiSCs, LiSCs, and CoCSCs, respectively [13,77].
We previously found intrinsic differences between SiSCs and LiSCs, with a tendency for cells
expanded from the large intestine to be more closely related to cancer than their small intestine
counterparts, possibly explaining why cancer is 20 times more prevalent in the large intestine than
the small intestine in humans [77]. Accordingly, while ID1 levels were statistically significant lower
in SiSCs with respect to CoCSCs, there was no significant difference between LiSCs and CoCSCs,
although ID1 levels tended to be higher in CoCSCs (Figure 5B). These observations seem to suggest
that ID1/ID1 could indeed mark cells with stemness features in our system. ID1/ID1 might be enriched
in the cell-of-origin of intestinal cancer besides being expressed by cancer-propagating cells possessing
stemness properties. Not only ID1, but also additional ID family members might identify cells with
these characteristics. Indeed, we found ID2-4 to also be expressed (Figure 5A). While ID1 was detected
in both cytoplasm and nucleus, ID2 and ID3 showed a clear nuclear expression, again confined to a
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subset of cells. Conversely, ID4 was weakly expressed (Figure 5A). IDs have been described as BMP4
targets in different cell types including embryonic stem cells [78]. In agreement with real-time PCR
arrays, BMP4 was highly expressed in tumor sections (Figure 5A). Potential activated pathways and
targets in R1-cell derived tumor xenograft are shown in Figure 6.
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Che otherapeutic resistance represents a ajor treat ent obstacle as ost cancer patients
ulti ately relapse, beco ing refractory to additional chemotherapeutic drugs.
Panels of che otherapy resistant cancer cell lines have been generated in order to establish
phenotypic signatures that might help predict chemotherapeutic sensitivity. However, despite
the number of reported studies, there is no standardized protocol for reproducible generation of
che otherapeutic resistant cells. Both pulse and incremental methods have been described. However,
a comparison of gene expression in the respective treatment-derivatives remains incomplete. Moreover,
to our knowledge, re-transplantation into an in vivo setting of such in vitro-established resistant cell
lines has been poorly studied.
In this study, e aimed at generating 5-FU resistant cells lines from five patient-derived
CRC stem cell lines previously isolated and characterized in our lab [13]. Our data suggested
that PTEN/MMAC1/TEP1 status could be a key determinant for successful generation of drug resistant
cells. Indeed, only Tu42 cells, which downregulated PTEN/ C1/TEP1, could survive long-ter
5-F treat ent. PTEN/M AC1/TEP1 is the most frequently inactivated tu or suppressor gene in
sporadic cancer [79] and acts by inhibiting cancer cell proliferation and invasiveness and pro oting
apoptosis through its antagonis of PI3 . Tu42 cells did not express PTE / C1/TEP1 in vitro;
ho ever, PTE / 1/TEP1 expression could be detected in Tu42 cell-derived tu or xenograft,
indicating reversible PTEN/ AC1/TEP1 loss in these cells.
e used two treatment regimens to generate resistant cells, and we compared the transcriptional
profiles of the resistant cell derivatives by focusing on almost 600 genes with roles in cell cycle,
DNA repair, apoptosis, stemness, metastasis, etabolism, and epigenetics. We identified similarities
and differences of 5-FU resistant cells generated by intermittent treatment with the IC50 drug dose
or continuous treatment with escalating drug doses. Similarities included upregulation of CA9,
MU 1, and CD24, and downregulation of HEY1, NANOG, and IL8. Similarities also included de
novo acquisition of two potent oncogenes with crucial roles in cell growth and proliferation, EGF
and MYC [80]. Despite these similarities, 5-FU resistant cells generated by continuous treatment
with escalating drug doses appeared to be less resistant than the other set of treated cells, showing
downregulation of numerous genes involved in invasion, metastasis, and angiogenesis, as well as
mTOR pathway downregulation. From a therapeutic standpoint, this data suggests that escalating
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the dose of chemotherapy might enhance efficiency. However, at the beginning of the treatment, cells
that are being treated with escalating drug doses might pose a threat. Indeed, our data of TRA-2-49
upregulation together with EpCAM, Muc2, and Villin downregulation in 20 µM 5-FU resistant cells
seems to suggest mechanisms of epithelial-mesenchymal transition, oncogenic dedifferentiation, and
acquisition of stemness features [81,82]. It is worth spending a few words on EpCAM because it
might help track phenotypic changes during chemotherapeutic treatment: EpCAM-expressing cells
proliferated in response to 10 µM 5-FU; later doubling of the 5-FU concentration resulted in the
downregulation of EpCAM, however EpCAM expression could be restored when the cells were
cultured in 3D matrices, which represents an assay of cell differentiation. This data highlights the
dynamic nature of CRC stem-like cells which undergo constant dynamic changes to adapt and survive
in adverse conditions.
By engrafting 5-FU resistant cells generated by intermittent treatment with the IC50 drug dose in
the mouse host, we confirmed the capacity of such cells to regenerate a tumor in vivo. The observation
that several genes implicated in stem cell maintenance and cancer progression were de novo expressed,
in vivo indicated that resistant cells continued to adapt in the new environment, even in the absence of
further chemotherapeutic insult.
Interestingly, while resistant cells generated by intermittent treatment with the IC50 5-FU dose
and control parental cells passaged in parallel did not differ for the expression of ID1 in vitro, ID1
was the top upregulated gene in the resistant cell-derived tumor xenograft as compared to the control
tumor xenograft. Using immunohistochemistry, we confirmed ID1 overexpression in the resistant
cell-derived tumor xenograft at the protein level. Both ID1 positive and negative cells could be
observed. The mechanisms driving this intratumoral heterogeneity remain to be fully investigated.
A tumor is a complex ecosystem of relatively differentiated cancer cells and CSCs as well as other cell
types. In the tumor, individual cells display a diverse set of characteristics and function together to
support the growth and maintenance of the tumor as a whole. ID1-expressing cells within the drug
resistant cancer cell pool might have preferentially proliferated following transplantation into the
mouse host, while the ID1-expressing cells within the untreated cancer cell pool might have had a
decreased proliferation potential. Emerging technologies including single-cell transcriptomics could
allow us to test our hypothesis and determine whether ID1 is restricted to a CSC subpopulation in the
primary colorectal tumor and is pervasively expressed in secondary lesions emerging after completion
of chemotherapy. Undoubtedly, our retrospective analysis of microarray ID1-expression indicated that
ID1 is already expressed in normal intestinal stem cells in accordance with a previous study [83], and
therefore, the ID1-expressing population might play a role in tumor initiation besides propagation.
In conclusion, our study connects the capacity for adaptation and propagation of CRC
stem-like cells after chemotherapeutic pressures, knowledge that could be exploited in future
therapeutic strategies.
4. Materials and Methods
4.1. Specimens
Tumor tissues were obtained by David Geller (surgeon, University of Pittsburgh Medical Center,
Pittsburgh, PA, USA) after informed consent in accordance with institutional review board (IRB)
protocols from patients with colorectal adenocarcinoma (IRB:PRO08010372).
4.2. Cell Culture and Determination of 5-FU IC50
Tu11, Tu14, Tu27, Tu28, and Tu42 CRC-stem like cells were cultured in Dulbecco’s Modified Eagle
Medium:Nutrient Mixture F-12 (DMEM/F12, Corning, cat. no. 10090CV; Fisher Scientific, Pittsburgh,
PA, USA) containing 1% insulin-transferrin-selenium (ITS, Corning, cat. no. 25800CR) and 0.5% fetal
bovine serum (FBS, Atlanta Biologicals, cat. no. S1245OH; Fisher Scientific). To establish 5-FU IC50,
cells were seeded onto 96-well plates (10,000 cells/well) in 100 µL of culture medium overnight, and
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then treated in triplicate with serial dilutions of 5-FU (10–250 µM) (Sigma-Aldrich, cat. no. F6627-1G;
Saint Louis, MO, USA). The number of viable cells was measured using the MTS-based CellTiter 96
AQueous Assay (Promega, cat. no. G3582; Madison, WI, USA) 72 h after drug exposure. 20 µL of the
MTS reagent were added to each well, and the absorbance was recorded at 490 nm after 4 h incubation
at 37 ◦C. Data were expressed as mean percentage (±SD) of cell numbers relative to control culture.
4.3. Cytotoxicity Assay
Tu27, Tu28, and Tu42 cells were seeded onto 96-well plates (10,000 cells/well) in 100 µL of culture
medium overnight, and then treated in triplicate with serial dilutions of 5-FU (10–500 µM) for 72 h.
The number of viable cells was measured as above described.
4.4. Establishment of 5-FU Resistant Cell Lines
Tu42 cells were treated with 100 µM 5-FU for 72 h. Surviving cells were allowed to recover
21 weeks in fresh media before a second pulse of the drug was given. Surviving cells were allowed to
recover additional 14 weeks before further applications (R1 cells). Alternatively, 5-FU resistant cell
lines (R2 cells) were established after six sequential treatments with 5-FU during an 8-month period
(5 µM and 100 µM, initial and final 5-FU concentration, respectively). Control parental cells were
passaged in parallel.
4.5. Organoid Preparation
Tu42 cells were suspended in 50µL Growth Factor Reduced (GFR) Matrigel (Corning, cat.no.
354230) and plated in tissue culture dishes at low density (50,000 cells/well of 48-well plate). After
solidification at 37◦C for 30 min, the Matrigel was overlaid with culture media. Whole intact Tu42
organoids were fixed 30 min in 4% PFA, and embedded in optimal cutting temperature compound
(OCT, Fisher Scientific, cat. no. 4853) for cryostat sectioning.
4.6. Immunostains
For immunofluorescence, tumor cells were detached using Trypsin/EDTA (Corning, cat. no.
25053CI). After rinsing in phosphate-buffered saline (PBS, Corning, cat. no. 21040CV), drops of the cell
suspension were directly placed onto microscope slides, air-dried, and fixed in cold acetone for 10 min.
Alternatively, cells were grown on Nunc Lab Tek 4-well chamber slides (Fisher Scientific, cat. no.
177437), air-dried, and fixed as above. Fixed slides containing cells or 5-micron-thick frozen sections
of organoids were washed with PBS, blocked with 3% bovine serum albumin (BSA, Fisher Scientific,
cat. no. 9048468) in 0.05% Tween 20-containing PBS (PBST) for 30 min, before incubation for 1 h
with antibodies against: Wheat germ agglutinin/Alexa Fluor 594 (Molecular Probes, cat.no. W11262;
Eugene, OR, USA), Lamin B1 (Abcam, cat. no. ab16048; Cambridge, MA, USA), SF2 (Abcam, cat. no.
ab38017), Fibrillarin (Abcam, cat. no. ab4566), Nucleostemin (Abcam, cat. no. ab70346), Nucleophosmin
(Abcam, cat. no. ab10530), PML (Abcam, cat. no. ab53773), Ki-67 (Abcam, cat. no. ab15580), TRA-2-49
(Abcam, cat. no. ab17973), EpCAM (Abcam, cat. no. ab32392), Muc2 (Santa Cruz, cat. no. sc-7314;
Santa Cruz, CA, USA), Villin (AbD Serotec, cat. no. MAB1671; Raleigh, NC, USA), phospho-S6RP
Ser235/236 (Cell Signaling Technology, cat. no. 4858; Boston, MA, USA) or phospho-S6RP Ser240/244
(Cell Signaling Technology, cat. no. 5364). After primary antibody incubation, slides were washed
three times with PBST and incubated, when necessary, with Alexa Fluor 488 and/or 594 conjugated
secondary antibody (Invitrogen; Carlsbad, CA, USA) for 30 min. Slides were washed as previously
described, and coverslips mounted onto slides using Hank’s Salt (HBSS, HyClone, cat. no. SH3026801;
Fisher Scientific) containing 50% glycerol (Fisher Scientific, cat. no. BP2291) and 10 µg/mL Hoechst
33342 (Molecular Probes, cat. no. H21492). Images were obtained using the Olympus IX71 inverted
fluorescence microscope (Olympus America, Center Valley, PA, USA).
For histological stains, 5mm tissues were fixed in 4% paraformaldehyde (PFA) overnight at 4 ◦C
and then stored in 70% ethanol until paraffin embedding. Paraffin blocks were cut into 7-micron-thick
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sections. Hematoxylin and eosin and Alcian blue stains were performed as described elsewhere.
For immunohistochemistry, paraffin sections were deparaffinized in xylene and rehydrated in graded
alcohol. Endogenous peroxidase was blocked using 3% hydrogen peroxide for 10 min. Antigen
unmasking was performed using 10 mM sodium citrate buffer pH 6.0. Reaction was carried out
using R.T.U. VECTASTAIN Universal ABC Kit (cat. no. PK-7800; Vector Laboratories, Burlingame,
CA, USA). Specifically, non-specific binding was blocked by incubating the slides in horse serum for
15 min. The slides were then exposed to primary antibodies against ID1 (LSBio, cat. no. LS-C165110;
Seattle, WA, USA), ID2 (LSBio, cat. no. LS-C50475), ID3 (LSBio, cat. no. LS-B3365), ID4 (LSBio, cat.
no. LS-B9923) or BMP4 (LSBio, Millipore, cat. no. ABD83) overnight at 4 ◦C, and later incubated
with VECTASTAIN biotinylated pan-specific universal secondary antibody for 10 min, followed by
VECTASTAIN streptavidin/peroxidase complex reagent for 5 min and ImmPACT DAB substrate
incubation (Vector Laboratories, cat. no. SK-4105). Immunostained sections were counterstained
with Gill’s hematoxylin, dehydrated with graded strengths of alcohols, cleared in xylene, and finally
coverslipped using a Permount mounting media (Fisher Scientific, cat. no. SP15-100).
4.7. RNA Extraction, cDNA Synthesis, PCR Arrays
Total RNA was isolated from cells or tissues stored in RNAlater reagent (QIAGEN, cat. no.
76104; Valencia, CA, USA) using the RNeasy Mini kit (QIAGEN, cat. no. 74104), according to the
manufacturer’s instructions. Potentially contaminating genomic DNA was digested using DNase
(QIAGEN, cat. no. 79254). Purity of isolated RNA was determined by measuring ratio of the optical
density of the samples at 260 and 280 nm. The OD260/280 ratio was ranging from 2.06 to 2.12 for
all samples. cDNAs were synthesized using the RT2 First Strand Kit (QIAGEN, cat. no. 330401).
QIAGEN’s RT2 PCR Array Human RNA QC (cat. no. PAHS-999Z) was used to test the quality of the
RNA samples before proceeding with the PCR arrays. A total of 588 genes were analyzed in duplicate
using the following QIAGEN’s RT2 Profiler PCR arrays: Human mTOR Signaling (cat. no. PAHS-098A),
Human Cancer Stem Cells (cat. no. PAHS-176A), Human Signal Transduction Pathway Finder (cat. no.
PAHS-014ZA), Human Damage Signaling Pathway (cat. no. PAHS-029ZA), Human Cancer Targets
(cat. no. PAHS-507ZA), Human Epigenetic Chromatin Modification Enzymes (cat. no. PAHS-085ZA),
and Human Epigenetic Chromatin Remodeling Factors (cat. no. PAHS-086ZA). 0.5 µg total RNA was
used for each plate. A StepOnePlus™ Real-Time PCR System (Applied Biosystems, Foster City, CA,
USA) was used for gene amplification. Dissociation (melting) curve analysis was performed to verify
PCR specificity. The analysis was performed automatically according to the SABiosciences company
web portal (QIAGEN), and further confirmed manually using the 2−∆∆Ct method. Changes in gene
expression obtained from two technical replicates were illustrated as fold regulations.
Levels of PTEN/MMAC1/TEP1 (204054_at; 217492_s_at; 204053_x_at) in short-term feeder-expanded
CRC stem cells (Tu11, Tu14, Tu27, Tu28, and Tu42) were retrieved from a microarray dataset previously
obtained in the laboratory (unpublished data). Levels of ID1 (208937_s_at) were retrieved from quantile
normalized microarray datasets of short-term feeder-expanded normal intestinal stem cells [77] and
CRC stem cells (Tu14, Tu18, Tu22, Tu25, Tu28, and Tu42) (unpublished data).
4.8. Ingenuity Pathway Analysis (IPA)
To identify biological functions perturbed in response to chemotherapy-induced selective pressure,
the dataset representing the log2 (fold change) of the expression level of 439 genes analyzed under
different culture conditions was imported into the QIAGEN’s IPA tool. Both core and comparison
analyses were performed. The following settings were used: the Ingenuity Knowledge Base (genes
only) database was used as a reference set; direct and indirect relationships were included, as well
as molecule relationships with endogenous chemicals, with a maximum of 35 focus molecules per
network and a maximum of 25 networks per analysis. All node types and data sources were included.
The confidence level was set to include experimentally observed relationships. Only human genes were
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included, and genes were filtered for colon cancer cell lines. All mutations were included. A 2-fold
cut-off on log2 (fold changes) was applied.
4.9. Flow Cytometry
Cells were incubated in the dark for 1 h with FITC Mouse Anti-Human CD24 (BD Pharmingen,
cat. no. 555427; San Diego, CA, USA) or FITC Mouse Anti-Human CD227 (BD Pharmingen, cat. no.
559774). Cells were centrifuged, washed three times, and the final cell pellet was resuspended in
400 µL of flow buffer with Sytox Blue dye (Molecular Probes, cat.no. S34857). Cells were analyzed
using a Miltenyi MACSQuant and FlowJo software (Tree Star, Inc; Ashland, OR, USA).
4.10. Animals
BALB/c nude mice were purchased from Charles River (Wilmington, MA, USA), and bred and
housed in the Division of Laboratory Animal Resources (DLAR) facility at the University of Pittsburgh.
Experimental protocols followed US National Institutes of Health (NIH) guidelines for animal care
and were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of
Pittsburgh. Tumor cells (2.5 × 105) were suspended in HBSS:Matrigel (1:1) and injected s.c. into both
flanks of 5-week-old mice (n = 3). Xenografted tumors were excised, fixed in buffered formalin and
embedded in paraffin for histological and immunohistochemical examination or stored in RNAlater
for RNA isolation.
4.11. Statistical Analysis
P-values for IPA predictions were calculated using Fisher’s exact test. A biofunction was
considered to be significantly activated or inhibited based on a z-score ≥2.0 or ≤−2.0, respectively and
p-value ≤ 0.01. Expression of pS6RP-S235/236 and pS6RP-S240/244 in parental, R1, and R2 cell-derived
colonies was compared using unpaired t-test with Welch’s correction. The expression intensities of ID1
in normal intestinal stem cells and colorectal CSCs were compared using unpaired t-test.
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